Annabelle Monnet

2.5k total citations · 2 hit papers
12 papers, 577 citations indexed

About

Annabelle Monnet is a scholar working on Neurology, Oncology and Economics and Econometrics. According to data from OpenAlex, Annabelle Monnet has authored 12 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Neurology, 3 papers in Oncology and 3 papers in Economics and Econometrics. Recurrent topics in Annabelle Monnet's work include Parkinson's Disease Mechanisms and Treatments (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Neurological disorders and treatments (3 papers). Annabelle Monnet is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (4 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers) and Neurological disorders and treatments (3 papers). Annabelle Monnet collaborates with scholars based in Switzerland, United Kingdom and United States. Annabelle Monnet's co-authors include Ramaswamy Govindan, Alessandra Bearz, Sai‐Hong Ignatius Ou, Walter Bordogna, Brett Hughes, Santiago Viteri, James Chih‐Hsin Yang, Dong‐Wan Kim, Bogdana Balas and Luigi De Petris and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Annabelle Monnet

11 papers receiving 567 citations

Hit Papers

Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Sma... 2015 2026 2018 2022 2015 2024 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
    2015 430 citations Sai‐Hong Ignatius Ou, Jin Seok Ahn et al. Journal of Clinical Oncology profile →
  2. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
    2024 56 citations Gennaro Pagano, Kirsten I. Taylor et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Annabelle Monnet Switzerland 5 408 374 171 84 63 12 577
Frédéric Boisserie United States 7 539 1.3× 590 1.6× 275 1.6× 83 1.0× 21 0.3× 11 950
Zachary Hornby United States 8 217 0.5× 193 0.5× 169 1.0× 79 0.9× 77 1.2× 14 376
Jung Hun Song South Korea 10 117 0.3× 285 0.8× 384 2.2× 92 1.1× 26 0.4× 10 757
JulieAnn Rader United States 6 165 0.4× 259 0.7× 304 1.8× 136 1.6× 140 2.2× 8 542
Curt J. Essenburg United States 9 106 0.3× 149 0.4× 180 1.1× 76 0.9× 61 1.0× 17 413
C. Morris United Kingdom 8 125 0.3× 248 0.7× 275 1.6× 93 1.1× 20 0.3× 19 494
Rebekka Unland Germany 8 221 0.5× 116 0.3× 351 2.1× 121 1.4× 26 0.4× 9 510
David Herrero‐Martín Spain 12 181 0.4× 140 0.4× 289 1.7× 109 1.3× 21 0.3× 12 467
Christina Vallbo Sweden 9 110 0.3× 201 0.5× 294 1.7× 111 1.3× 17 0.3× 11 452
Ei Nakayama Japan 11 335 0.8× 320 0.9× 243 1.4× 104 1.2× 25 0.4× 19 663

Countries citing papers authored by Annabelle Monnet

Since Specialization
Citations

This map shows the geographic impact of Annabelle Monnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annabelle Monnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annabelle Monnet more than expected).

Fields of papers citing papers by Annabelle Monnet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annabelle Monnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annabelle Monnet. The network helps show where Annabelle Monnet may publish in the future.

Co-authorship network of co-authors of Annabelle Monnet

This figure shows the co-authorship network connecting the top 25 collaborators of Annabelle Monnet. A scholar is included among the top collaborators of Annabelle Monnet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annabelle Monnet. Annabelle Monnet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Pagano, Gennaro, Dylan Trundell, Tanya Simuni, et al.. (2025). Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials. npj Parkinson s Disease. 11(1). 193–193.
2.
Trundell, Dylan, Evan Davies, Stefano Zanigni, et al.. (2025). Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III. Journal of Parkinson s Disease. 15(1). 97–110. 2 indexed citations
3.
Pagano, Gennaro, Annabelle Monnet, Benjamin Ribba, et al.. (2024). Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial. Nature Medicine. 30(12). 3669–3675. 14 indexed citations
4.
Ribba, Benjamin, Kenneth Marek, Andrew Siderowf, et al.. (2024). Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials. Journal of Parkinson s Disease. 14(6). 1225–1235. 3 indexed citations
5.
Pagano, Gennaro, Kirsten I. Taylor, Tanya Simuni, et al.. (2024). Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease. Nature Medicine. 30(4). 1096–1103. 56 indexed citations breakdown →
6.
Pagano, Gennaro, Annabelle Monnet, Tanya Simuni, et al.. (2024). Exploratory Analysis of PASADENA Open-label Extension Evaluating the Effect of Prasinezumab on the Progression of Motor Signs and Symptoms (S30.006). Neurology. 102(7_supplement_1). 1 indexed citations
7.
Zanigni, Stefano, Dylan Trundell, Annabelle Monnet, et al.. (2022). Estimating the meaningful within-patient change threshold for the MDS-UPDRS Part III (P1-1.Virtual). Neurology. 98(18_supplement). 1 indexed citations
8.
Montesinos, Pau, Benjamin M. Beckermann, Olivier Catalani, et al.. (2020). MIRROS: A Randomized, Placebo-Controlled, Phase III Trial of Cytarabine ± Idasanutlin in Relapsed or Refractory Acute Myeloid Leukemia. Future Oncology. 16(13). 807–815. 57 indexed citations
9.
Kamdar, Manali, Bradley Augustson, Young Rok, et al.. (2020). Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study. Blood. 136(Supplement 1). 30–31. 3 indexed citations
10.
Rufibach, Kaspar, Dominik Heinzmann, & Annabelle Monnet. (2019). Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia. Pharmaceutical Statistics. 19(1). 44–58. 3 indexed citations
11.
Montesinos, Pau, Jordi Esteve, Marina Konopleva, et al.. (2019). MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology. 37(15_suppl). TPS7063–TPS7063. 7 indexed citations
12.
Ou, Sai‐Hong Ignatius, Jin Seok Ahn, Luigi De Petris, et al.. (2015). Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study. Journal of Clinical Oncology. 34(7). 661–668. 430 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric Boisserie Breakdown of academic impact, for papers by Zachary Hornby Breakdown of academic impact, for papers by Jung Hun Song Breakdown of academic impact, for papers by JulieAnn Rader Breakdown of academic impact, for papers by Curt J. Essenburg Breakdown of academic impact, for papers by C. Morris Breakdown of academic impact, for papers by Rebekka Unland Breakdown of academic impact, for papers by David Herrero‐Martín Breakdown of academic impact, for papers by Christina Vallbo Breakdown of academic impact, for papers by Ei Nakayama
Rankless by CCL
2026